Second patient death reported with gene therapy for muscular dystrophy
Washington: Shares of
Sarepta
Therapeutics
plunged Monday after the
biotech
drugmaker
reported a second death in connection with its
gene therapy
for
muscular dystrophy
.
Sarepta reported the death over the weekend and provided additional details about its response, which includes pausing shipments of the therapy, Elevidys, for older patients who are no longer able to walk. The one-time treatment is approved for children with a genetic variant of Duchenne's muscular dystrophy, which causes weakness, loss of mobility and early death in males.
Elevidys is the first gene therapy approved in the U.S. for the rare muscle-wasting condition, but it has faced scrutiny since its accelerated approval in 2023.
The second death, like an earlier one reported in March, occurred in a teenage boy who suffered a fatal case of acute liver injury, a known side effect of the therapy. Older patients receive a larger dose of the therapy.
Sarepta said it would pause a study in those patients and assemble an
expert panel
to recommend new safety protocols for taking the drug. Those changes are expected to include increased use of immune-system suppressing drugs, company executives said Monday. The liver injury associated with the therapy is thought to be connected to the immune system's response.
Sarepta said it was cooperating with the Food and Drug Administration, which would have to sign off on any changes to the product's use.
Elevidys received expedited approval despite concerns from some
FDA
scientists about its effectiveness in treating Duchenne's.
The FDA granted full approval last year and expanded the therapy's use to patients 4 years and older, regardless of whether they are still able to walk. Previously it was only available for younger patients who were still walking.
Shares of the Cambridge, Massachusetts-based company fell more than 42% to close at about $21 in trading.
Wall Street analysts speculated that FDA officials, including new vaccine chief Dr. Vinay Prasad, might impose more restrictions on the drug or even block its use. Prasad has been highly critical of the therapy since its approval under the agency's previous leadership.
"Now with two deaths reported in this segment of the market, it seems incrementally more possible that the FDA could step in and remove the therapy from the market in non-ambulatory patients," said Leerink Partners analyst Joseph Schwartz, in a Sunday research note.
Elevidys uses a disabled virus to insert a replacement gene for producing dystrophin into patient cells. It costs $3.2 million for a one-time infusion.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Torrent Pharma keen to break into big league
Ahmedabad-based Torrent Pharma is revving up for acquisitions in India as part of its plans to break into the top three drugmakers over a span of three to five years. Currently at seventh position by market share, Torrent has dramatically scaled up its India operations over the last five years with bolt-on deals for leading brands and small companies. For FY25, Torrent had sales of Rs 11,516 crore, of which India contributed Rs 6,393 crore. In the first media interaction following the announcement of his new role starting August 1, Aman Mehta , managing director-designate at Torrent Pharma, told ET that the commitment to the Indian market remains as strong as ever. "To be in the top three looks to be an ambitious but realistic goal," he said. "Even with some of the structural changes that are happening or have happened in the recent years, we believe that the inherent demand of the Indian pharma market is not going to change." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villa For Sale in Dubai Might Surprise You Villas in Dubai | Search ads Learn More Undo His confidence stems from a consistent growth in the Indian market compared to those like US or Europe that have been under pressure due to regulatory challenges and a headlong drop in prices of generic drugs. On a 12-month moving annual total (MAT) basis, the Indian pharma market has grown at 7.2% to Rs 2.29 lakh crore ($26.7 billion) in May. That growth is led by a mix of drugs for cardiac issues, gastrointestinal products, anti-infectives, anti-diabetes, vitamins and respiratory issues. But for Torrent, the task to take the third rank will be a tough one. Torrent must have a faster growth rate to topple giants such as Cipla , Alkem and Intas Pharma. Sun Pharma and Abbott lead the stack as the top two in the Indian market. Live Events Torrent's deals-led growth strategy is already in play. In 2022, the company shelled out Rs 2,000 crore for private equity-backed Curatio Healthcare, makers of popular cosmetic dermatology brands. More recently in December, it lapped up a set of new generation medicines to treat diabetes from German drug maker Boehringer Ingelheim. A year later in 2023, Torrent came close to buying Cipla for an audacious $7 billion deal. Although it could not be officially confirmed, the talks failed on valuation mismatch. Torrent was also named as a frontrunner to acquire a majority stake in JB Pharma from private equity firm KKR, but that deal was also called off, at least temporarily. Mehta, who has steered most deal discussions for Torrent, says the company is at a stronger position to invest further and grow business. Sheetal Sapale, VP, PharmaTrac, a data intelligence firm that tracks medicine sales, said Torrent Pharma's revenue has grown 1.6x in the last five years, with cardiac treatments making up over a fourth of its domestic sales. She added that strategic acquisitions have helped Torrent consolidate its position in pain drugs, gastrointestinal medicines and skin care range. In the last four years, Torrent has expanded its field force. From 3,600, that may now double to 7,000 medical representatives this year, which Mehta called "methodical expansion for better territorial reach".
Time of India
2 hours ago
- Time of India
Gummy Vitamin recall: FDA Flags B12 supplements sold on Amazon, Aldi — See which brands are affected
Details of the Recalled Products Welby (sold at Aldi): 1,000 mcg B12, 140-count bottle; UPC: 4099100290868 Berkley Jensen (sold at BJ's Wholesale Club): 1,000 mcg B12, 250-count bottle; UPC: 888670132487 VitaGlobe (sold online, including Amazon): Extra Strength B12, 60-count bottle; UPC: 850005214670 No Reports of Illness Yet, Recall Issued as Precaution Live Events Routine Testing Triggered the Recall What Consumers Should Do FAQs Why were the B12 gummy vitamins recalled? Have there been any reported health incidents linked to the gummy vitamin recall? (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel A batch of gummy vitamins sold across major U.S. retailers including Amazon, Aldi, and BJ's Wholesale Club has been voluntarily recalled following the detection of a potentially dangerous undeclared allergen. The move was announced by Vita Warehouse Corp. on June 12, following standard allergen testing procedures initiated by one of the recall applies to specific lots of B12 gummy vitamins marketed under the brand names Welby , Berkley Jensen, and VitaGlobe . The U.S. Food and Drug Administration (FDA) confirmed in a public advisory that the recalled products may contain traces of peanuts, posing a risk to individuals with allergies or severe affected Gummy Vitamins, as mentioned in a report by USA Today, have been identified as follows:All three products belong to the Lot Number 248046601 and carry an expiration date of October 2026. The packaging consists of clear bottles with white caps and variations in label colors. The lot number and expiry date are printed on the bottom of the to the FDA, there have been no confirmed illnesses or allergic reactions linked to the consumption of the affected vitamin gummies. Nonetheless, the recall was issued 'out of an abundance of caution,' especially in light of the potentially severe consequences for peanut-allergic allergies can lead to life-threatening reactions, including anaphylaxis. The FDA has urged consumers with known sensitivities to immediately discontinue use of the identified allergen was flagged during routine label-verification testing by Aldi. Although Vita Warehouse Corp.'s own testing did not detect peanut residue, the single adverse result was enough to initiate a recall. The FDA stated that the retailer's protocol included verification of a 'does not contain peanuts' claim, which one product reportedly the agency has clarified that no other products under the Welby, Berkley Jensen, or VitaGlobe brand names are impacted by this in possession of the recalled products—particularly those with peanut allergies—are advised to return the items to their point of purchase for a full refund or dispose of them safely. The FDA has emphasized that anyone experiencing symptoms of an allergic reaction should seek immediate medical with questions can reach Vita Warehouse Corp. via their toll-free helpline at 1-855-214-0100 (Monday through Friday, 7:30 a.m. to 4:00 p.m. EST).The recall was issued after routine testing detected the presence of an undeclared allergen—peanut residue—in one of the products. While no illnesses have been reported, the recall was initiated as a precaution to protect consumers with peanut the U.S. Food and Drug Administration (FDA) confirmed there have been no illnesses or allergic reactions reported so far. The recall was issued as a preventive measure.
Mint
5 hours ago
- Mint
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why
US-based multinational pharmaceutical giant Eli Lilly & Co., on Tuesday, 17 June 2025, announced its plans to acquire gene-editing biotech firm Verve Therapeutics Inc. for $1.3 billion as the big pharma company eyes expansion in experimental medicine for long-term growth, reported the news agency Bloomberg. According to the agency report, Eli Lilly & Co. will pay up to $13.50 per share for the acquisition deal. The breakdown of the deal will be that Eli Lilly & Co. will pay $10.50 per share in cash as well as a non-tradeable contingent value right that entitles the holder to receive as much as $3 extra per share. The transaction is expected to close in the third quarter of the current year, reported the news agency, citing the company. Verve Therapeutics shares skyrocketed 75.12% to $10.99 at the US stock market open at 9:38 a.m. (EDT), compared to $6.27 at the previous market close. However, pharma major Eli Lilly & Co. shares are trading 1.45% lower on Wall Street at $795.84 as of 9:40 a.m. (EDT), compared to $807.58 at the previous stock market close. The US big pharma company Eli Lilly & Co.'s revenues are centred around its iconic weight-loss drug, Zepbound, as the company prepares for the medicine's patent to expire. The news agency reported that the company has been able to target experimental medicines that are still far from the market. In this area, price tags are usually smaller than for therapies that have already undergone multiple patient trials. The long-term return on such early-stage deals can be far larger. In January 2025, Eli Lilly & Co. agreed to pay up to $2.5 billion for a cancer medicine which was being tested by Scorpion Therapeutics Inc., as per the agency report. Further in May, the company announced a plan to buy SiteOne Therapeutics Inc., a biotech firm developing pain medicines, for nearly $1 billion. Eli Lilly & Co. was reportedly in collaboration with Verve Therapeutics on its experimental gene-editing program for reducing lipoprotein, which is a risk factor for plaque buildup in human arteries. This acquisition deal will give Eli Lilly & Co. full control of the program, as the company shows confidence in its gene editing drug, which is a cutting-edge technology in the market, according to the report. However, this technology has struggled to attract investors recently, in part because it's expensive to make and aimed at providing one-time cures for rare diseases that may not be lucrative. Verve is a rare example of a gene editing company targeting a disease that affects a large population and offering better commercial prospects. Its approach, which uses tiny balls of fat to deliver the treatment, is less expensive to make than other gene therapies. Ruth Gimeno, the Vice President for diabetes and metabolic research and development at Eli Lilly & Co., told the news agency that the experimental therapy could be the first to edit genes inside a living body that's targeted to a broad population of patients.
